BioPharmX: Phase 2b Trial Of BPX-04 Meets Primary, Secondary Endpoints

(RTTNews) - BioPharmX Corp. (BPMX), a specialty pharmaceutical company focused on medical dermatology products, announced Tuesday positive results from its Phase 2b clinical trial of BPX-04 for papulopustular rosacea.

In pre-market activity, BioPharmX shares were gaining around 62 percent to trade at $1.43.

BPX-04 is a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea.

The randomized, double-blind, vehicle-controlled Phase 2b trial enrolled 206 subjects aged 18 years and above with moderate-to-severe papulopustular rosacea. The study evaluated the safety and efficacy of once daily application of BPX-04, versus a vehicle control over a 12-week treatment period.

The company noted that BPX-04, a 1% minocycline gel, successfully met both the primary and secondary endpoints of the trial. It demonstrated a statistically significant mean change in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear on the Investigator's Global Assessment or IGA scale from baseline to week 12.

David Tierney, BioPharmX CEO, said, "Based on the efficacy and safety profile, we believe BPX-04 has the potential to be the best-in-class treatment for papulopustular rosacea."